Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease
Khayat, André Salim; Guimarães, Adriana Costa; Cardoso, Plínio Cerqueira; Lima, Patrícia Danielle Lima de; Bahia, Marcelo de Oliveira; Antunes, Lusânia M. Greggi; Burbano, Rommel Rodríguez.
Genet. mol. biol
; 27(1): 115-117, 2004. ilus, tab
Artigo
em Inglês
| LILACS | ID: lil-357883
Hydroxyurea is commonly used in the treatment of myeloproliferative diseases and in patients with sickle cell disease (SCD). The use of this antineoplastic agent in patients with SCD is justified because of the drug's ability to increase fetal hemoglobin levels, thereby decreasing the severity of SCD. However, high doses or prolonged treatment with hydroxyurea can be cytotoxic or genotoxic for these patients, with an increased risk of developing acute leukemia. This danger can be avoided by monitoring the lymphocytes of patients treated with hydroxyurea. Cytogenetic tests are important endpoints for monitoring the physiological effects of physical and chemical agents, including drugs. In this work, we assessed the genotoxicity of hydroxyurea in short-term cultures of lymphocytes from SCD patients. Hydroxyurea was not cytotoxic or genotoxic at the concentrations tested in the G2 phase of the cell cycle. These results support the use of hydroxyurea in the treatment of SCD, although further work is necessary to understand the effects of this drug in vivo.
Biblioteca responsável:
BR26.1
Texto completo
Documentos relacionados